| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5832724 | International Immunopharmacology | 2014 | 14 Pages |
Abstract
DC-CIK immunotherapy is a safe and effective treatment for patients with malignant tumors. Further clinical trials to provide supportive evidence for the routine use of DC-CIK therapy in clinical practice are warranted.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ran Chen, Xin Deng, Haochen Wu, Peichun Peng, Bin Wen, Fuyin Li, Fenfen Li,